Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Endocrinology | Internal Medicine | Orthopedics | Journal

Back to Journal Articles

Sex Steroid Levels Linked to Fractures in Elderly Men

Last Updated: August 17, 2009.

 

Estradiol, testosterone may be clinically useful in determining fracture risk

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Levels of sex steroids such as estradiol and testosterone affect the risk of fractures in elderly men, according to a study published online July 7 in the Journal of Clinical Endocrinology & Metabolism.

MONDAY, Aug. 17 (HealthDay News) -- Levels of sex steroids such as estradiol and testosterone affect the risk of fractures in elderly men, according to a study published online July 7 in the Journal of Clinical Endocrinology & Metabolism.

Erin S. LeBlanc, M.D., from Oregon Health & Science University in Portland, and colleagues examined the association between fracture risk and sex steroid levels in 1,738 elderly men plus 342 elderly men who experienced a non-vertebral fracture.

The researchers found that the risk of non-vertebral fractures was highest in men in the lowest quartile of bioavailable estradiol (bioE2, adjusted hazard ratio, 1.5) or highest quartile of sex hormone binding globulin (SHBG, adjusted hazard ratio, 1.4). There was no increased risk in men in the lowest quartile of bioavailable testosterone (bioT) after adjusting for bioE2. In men with high SHBG, low bioT was associated with a higher fracture risk (adjusted hazard ratio, 2.1). The highest risk was in men with low bioE2, low bioT, and high SHBG (adjusted hazard ratio, 3.4).

"Our results suggest that bioavailable sex steroid and SHBG measurements may be useful in the clinical assessment of fracture risk in older men, and that the physiological implications of hypogonadism should be considered in light of possible interactions among sex steroids and SHBG," LeBlanc and colleagues conclude.

Merck and Co., Eli Lilly, and Amgen provided support for the study, and one co-author reported financial ties to these companies.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: Childbearing Shown to Increase Risk of Metabolic Syndrome Next: Histology Can Reduce Cancer Risk After Abnormal Pap Smear

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.